2. MAPK/ERK Pathway Apoptosis Metabolic Enzyme/Protease Immunology/Inflammation NF-κB
  3. p38 MAPK Apoptosis Reactive Oxygen Species (ROS) Caspase Bcl-2 Family
  4. PPIA-IN-1

PPIA-IN-1 is a PPIA inhibitor with a Kd value of 0.52 μM. PPIA-IN-1 inhibits the PPIA/MAPK signaling pathway to exert antiproliferative activity. PPIA-IN-1 induces G0/G1 cell cycle arrest in cancer cells. PPIA-IN-1 upregulates the expression of Bax and caspase-3, downregulates Bcl-2 expression, and induces apoptosis in cancer cells. PPIA-IN-1 induces increased ROS levels, DNA damage, endoplasmic reticulum stress, and mitochondrial dysfunction in cancer cells. PPIA-IN-1 exhibits antitumor activity in a mouse colon cancer xenograft model. PPIA-IN-1 can be used for the research of colorectal cancer.

For research use only. We do not sell to patients.

PPIA-IN-1

PPIA-IN-1 Chemical Structure

CAS No. : 3077886-94-0

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

PPIA-IN-1 Related Antibodies

Top Publications Citing Use of Products

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PPIA-IN-1 is a PPIA inhibitor with a Kd value of 0.52 μM. PPIA-IN-1 inhibits the PPIA/MAPK signaling pathway to exert antiproliferative activity. PPIA-IN-1 induces G0/G1 cell cycle arrest in cancer cells. PPIA-IN-1 upregulates the expression of Bax and caspase-3, downregulates Bcl-2 expression, and induces apoptosis in cancer cells. PPIA-IN-1 induces increased ROS levels, DNA damage, endoplasmic reticulum stress, and mitochondrial dysfunction in cancer cells. PPIA-IN-1 exhibits antitumor activity in a mouse colon cancer xenograft model. PPIA-IN-1 can be used for the research of colorectal cancer[1].

In Vitro

PPIA-IN-1 (Compound 20b) potently inhibits the proliferation of HeLa, HCT116, MCF-7, SW480, CT26, Panc-1 and HepG-2 cells, with IC50 values of 0.69, 0.51, 1.19, 2.59, 0.86, 3.31 and 2.16 μM[1].
PPIA-IN-1 (0-1.2 μM; 24 h) reduces the colony-forming ability of HCT116 cells and inhibits cell migration and invasion[1].
PPIA-IN-1 (0-1.2 μM; 48 h) dose-dependently arrests HCT116 cells at the G0/G1 phase and downregulates the expression of cyclin A2 and CDK4[1].
PPIA-IN-1 (0-1.2 μM; 48 h) induces apoptosis in HCT116 cells, upregulates the expression of Bax and caspase-3, and downregulates the expression of Bcl-2 protein[1].
PPIA-IN-1 (0-1.2 μM; 48 h) increases the intracellular ROS level in HCT116 cells[1].
PPIA-IN-1 (0-1.2 μM; 48 h) inhibits DNA synthesis and proliferation of HCT116 cells, induces cellular DNA damage, and upregulates the expression of γ-H2AX and p53[1].
PPIA-IN-1 (0.3-1.2 μM; 48 h) dose-dependently activates endoplasmic reticulum stress and upregulates the expression of PERK, ATF4 and CHOP in HCT116 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PPIA-IN-1 Related Antibodies

Cell Migration Assay [1]

Cell Line: HCT116 cells
Concentration: 0 μM, 0.3 μM, 0.6 μM, 1.2 μM
Incubation Time: 24 h
Result: Inhibited scratch wound closure by HCT116 cells in a dose-dependent manner.
Caused significant reductions in migration at all tested concentrations compared to the control group.

Cell Cycle Analysis[1]

Cell Line: HCT116 cells
Concentration: 0 μM, 0.3 μM, 0.6 μM, 1.2 μM
Incubation Time: 48 h
Result: Caused a dose-dependent increase in the percentage of HCT116 cells in the G0/G1 phase.
Induced a dose-dependent decrease in the percentage of cells in the S and G2/M phases.
Downregulated the expression of cell cycle-related proteins cyclin A2 and CDK4 in a dose-dependent manner.

Apoptosis Analysis[1]

Cell Line: HCT116 cells
Concentration: 0 μM, 0.3 μM, 0.6 μM, 1.2 μM
Incubation Time: 48 h
Result: Induced apoptosis in HCT116 cells in a dose-dependent manner, as shown by increased Annexin V-positive cells.
Upregulated the expression of pro-apoptotic proteins Bax and cleaved caspase-3 in a dose-dependent manner.
Downregulated the expression of anti-apoptotic protein Bcl-2 in a dose-dependent manner.
In Vivo

PPIA-IN-1 (15-45 mg/kg; i.p.; once daily; for 14 consecutive days) exhibits potent, dose-dependent antitumor efficacy in the CT26 colon cancer xenograft model of BALB/c mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (22 g, 3 male and 3 female per group, CT26 colon cancer cells injected subcutaneously to form xenograft tumors)[1]
Dosage: 15 mg/kg; 45 mg/kg
Administration: i.p.; daily; 14 days
Result: Showed significant dose-dependent inhibition of tumor growth compared to the vehicle group.
Reduced tumor weight and volume in a dose-dependent manner, with 45 mg/kg having greater effect than 15 mg/kg.
Caused no significant changes in body weight, unlike 5-FU (HY-90006) and CsA (HY-B0579).
Increased necrosis regions in tumor tissue as revealed by H&E staining.
Caused no obvious injury or abnormality in major organs.
Markedly decreased Ki67 protein levels in tumor tissue.
Molecular Weight

555.34

Formula

C23H21Cl2FN4O7
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(C1(C(OCC)=O)OC(C2=CC=CC=C2F)N3C1N(C(C(OC)=O)=C)C4=NC(Cl)=NC(Cl)=C34)OCC
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (180.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.8007 mL 9.0035 mL 18.0070 mL
5 mM 0.3601 mL 1.8007 mL 3.6014 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (4.50 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (4.50 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.8007 mL 9.0035 mL 18.0070 mL 45.0175 mL
5 mM 0.3601 mL 1.8007 mL 3.6014 mL 9.0035 mL
10 mM 0.1801 mL 0.9003 mL 1.8007 mL 4.5017 mL
15 mM 0.1200 mL 0.6002 mL 1.2005 mL 3.0012 mL
20 mM 0.0900 mL 0.4502 mL 0.9003 mL 2.2509 mL
25 mM 0.0720 mL 0.3601 mL 0.7203 mL 1.8007 mL
30 mM 0.0600 mL 0.3001 mL 0.6002 mL 1.5006 mL
40 mM 0.0450 mL 0.2251 mL 0.4502 mL 1.1254 mL
50 mM 0.0360 mL 0.1801 mL 0.3601 mL 0.9003 mL
60 mM 0.0300 mL 0.1501 mL 0.3001 mL 0.7503 mL
80 mM 0.0225 mL 0.1125 mL 0.2251 mL 0.5627 mL
100 mM 0.0180 mL 0.0900 mL 0.1801 mL 0.4502 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PPIA-IN-1 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PPIA-IN-13077886-94-0p38 MAPKApoptosisReactive Oxygen Species (ROS)CaspaseBcl-2 FamilyMCF-7 cellHCT116 cellCT26 cellHeLa cellPPIAPanc-1 cellSW480 cellHepG-2 cellcolorectal cancerMAPK signaling pathwayBALB/c miceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PPIA-IN-1
Cat. No.:
HY-172209
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.